{"entity":{"id":"nct02586857","kind":"trial","name":"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)","aka":[],"tldr":"A phase 1/2 trial of ACP-196 in glioma & glioblastoma, run by Acerta Pharma BV, active and no longer recruiting.","summary":"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) is a phase 1/2 interventional study registered as NCT02586857 by Acerta Pharma BV, with 24 participants enrolled, started 2016-01-25 and due to reach its primary completion in 2020-06-26. Interventions recorded: ACP-196. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02586857","url":"https://clinicaltrials.gov/study/NCT02586857"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02586857","phase":"1/2","setting":"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)","sponsor":"Acerta Pharma BV","started":"2016-01-25","startedType":"actual","yearReported":2020,"enrolled":24,"enrolledBasis":"registry","outcomes":[{"endpoint":"Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.","primary":true,"unit":"participants","arms":[{"name":"Cohort 1","n":15,"value":1,"note":"Figures from the ClinicalTrials.gov results section (first posted 2020-07-29), not from a publication"},{"name":"Cohort 2","n":9,"value":1}],"source":"https://clinicaltrials.gov/study/NCT02586857?tab=results"}]},"route":"/trials/nct02586857/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}